Skip to content
DataLookout
Start free
Menu

Black Diamond Therapeutics, Inc. clinical trial pipeline

Get alerts when Black Diamond Therapeutics, Inc.'s trials change
Data updated daily from ClinicalTrials.gov, last refresh 2026-11-05

What changed in the last 30 days

1 trial changed in the last 30 days: 0 stopped, 0 with notable changes, 1 with a minor change only.

  1. Minor: Silevertinib With Temozolomide · Newly Diagnosed GBM With Unmethylated MGMT and EGFRvIII Trial sites expanded: 34 → 38 locations Black Diamond Therapeutics, Inc.Phase 2 NCT07326566
  • Stopped: terminated, suspended or withdrawn
  • Notable: the plan changed
  • Minor: routine updates

Active trials by phase

Phase 1/2
1
Phase 2
1

Disease areas by active trials

Glioblastoma (1) · Glioma (1) · Lung Cancer (1) · Non-Small Cell Lung Cancer (NSCLC) (1)

Get alerts when Black Diamond Therapeutics, Inc.'s trials change
Status changes, date slips, and new filings: detected daily, delivered to your inbox.
Start monitoring free